Digital Monitoring in Cancer Survivors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-11-11

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Digital monitoring in cancer survivors WHY? There is a large amount of evidence to suggest that addressing a cancer patients' quality of life and symptoms has a positive impact on their wellbeing and experience with care. Finding ways of accurately and timely measuring Patient Reported Outcomes (PROs), along with developing electronic and mobile health (eHealth and mHealth) solutions, is being increasingly recognized as one way to manage patients' quality of life and symptoms without increasing burden on time and resource-stretched National Health Services.

WHAT? The main objective of this study is to assess the feasibility of administering routine self assessment through questionnaire called the Edmonton Symptom Assessment System (ESAS) via MS Forms associated with continuous wearing of a smart watch in cancer survivors. We also hope to identify predictors of attrition or dissatisfaction.

WHO? Adult outpatients with controlled cancer undergoing surveillance (cancer survivors) WHERE? Participants will be identified through attendance in oncology outpatient clinics by the oncologist in charge.

HOW? Participants will receive a smart watch and smart phone (or an App downloaded onto their own phone). The smart watch will record physical activity , sleep patterns and other data such as heart rate and participants are expected to wear the watch all the time for about 4 months. Participants will also attend the hospital for a research appointment at the start and the end of the research and complete questionnaires weekly throughout the study, delivered via MS forms. At the end of the study the patients will be invited to a focus group to discuss their experience. The study will last for 18 months; each participants' involvement will be for about 4 month.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pro-active Monitoring of Vital Signs in Oncology Patients Using a Smartwatch

NCT06680778

Cancer Emergencies

RECRUITING

Feasibility of Remote Activity Assessment and PRO Collection Among Transgender Cancer Survivors

NCT05391217

Neoplasms Chronic Disease

RECRUITING

Feasibility of Monitoring Cancer Patients With a Smart T-shirt: Protocol for the OncoSmartShirt Study

NCT05235594

Cancer

COMPLETED NA

Effects of Personalized Exercise Prescriptions Through Mobile Health on Physical Activity and Health Outcomes in the Cancer Survivors

NCT06840028

Cancer Survivors Chronic Disease Physical Activity +3 more

RECRUITING NA

EORTC Quality of Life Measurement Strategies in Progressive Cancer

NCT06842654

Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cancer surviviors

Cancer Survivors who are on a scheduled therapeutic break or having completed cancer treatments,

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Diagnosis of any solid malignancy, at any stage

* Completion of treatment (including surgery, radiotherapy, and any kind of cytotoxic systemic anticancer treatment \[hormonal and targeted treatments allowed\])
* Clinical, biochemical and radiological confirmation of controlled disease (no evidence of residual disease or not-progressive disease)
* Scheduled for either a therapeutic break (from cytotoxic systemic anticancer treatment), or having completed the planned multimodal treatment
* Scheduled for active surveillance plan within oncology service or discharged to surgical or GP care following completion of adjuvant treatment
* Male or female patients aged at least 18 years old
* WHO Performance Status 0-2

Exclusion Criteria

* • Not in possession of a SIM card

* No internet access through Wi-Fi or unwilling to use mobile data allowance on a daily basis
* Unable to understand and follow the instructions autonomously
* Uncontrolled severe comorbidities (I.e., cardiovascular, neurological, respiratory)
* Lack of capacity
* Unable to understand English
* Still undergoing systemic anticancer treatment (apart from bone-targeted agents, hormonal treatment against breast or prostate cancers or maintenance monoclonal antibody monotherapy)
* Poor general condition (PS\>2)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No